DeutschNewstral
Article
jdsupra.com on 2024-03-07 19:40
Biocon Settles with Bayer and Regeneron, Securing Canada Market Entry Date for Aflibercept Biosimilar
Related news
- PTAB Institutes Celltrion and Biocon IPRs on Regeneron Aflibercept Dosing Patentjdsupra.com
- EYLEA® Biosimilar Updates: Sandoz’s Enzeevu™ (aflibercept-abzv) FDA Approved, Regeneron Dismisses IPR Appealsjdsupra.com
- Viatris and Biocon Biologics Launch Bevacizumab Biosimilar ABEVMY in Canadajdsupra.com
- Biosimilar Deals Updates: Biocon, AstraZenecajdsupra.com
- Biocon Settles with Janssen, Securing U.S. Market Entry Date for Ustekinumab Biosimilarjdsupra.com
- Mylan Files IPR on Regeneron Aflibercept Patentjdsupra.com
- EYLEA (Aflibercept) Biosimilar Development Updates (Part 2)jdsupra.com
- Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilarjdsupra.com
- Regeneron v. Mylan - Update on Aflibercept BPCIA Litigationjdsupra.com
- Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Casejdsupra.com
- Regeneron Dismisses IPR Appeals and Disclaims EYLEA® (aflibercept) Patentjdsupra.com
- Expedited Trial Ordered in Regeneron Aflibercept BPCIA Case Against Mylanjdsupra.com
- Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patentjdsupra.com
- Post-Trial Updates on Regeneron v. Mylan (Aflibercept) BPCIA Litigationjdsupra.com
- Celltrion Announces Phase III Results for Aflibercept Biosimilarjdsupra.com
- Celltrion begins Phase 3 trial of aflibercept biosimilarjdsupra.com
- Sandoz to begin Phase III trial of aflibercept biosimilarjdsupra.com
- Updates on Aflibercept Biosimilar Approvals and BPCIA Litigationjdsupra.com
- Fifth EYLEA® Biosimilar FDA-Approved: Amgen’s Pavblu™ (aflibercept-ayyh)jdsupra.com
- Regeneron Identifies Six Patents for Expedited Trial in BPCIA Aflibercept Case Against Mylanjdsupra.com